Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Fax: 240 631 3203

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Suite 400, Gaithersburg, United States

Unicorn2020 Sep. 13 at 5:31 PM

$EBS Covered all my shorts at $4.75 and bought back 50K shares on Thursday at $5.52. I have a strong feeling something significant is going to happen here within the next six months. I'm positioned and ready.

1 · Reply

billywilliamz Sep. 11 at 8:56 PM

$EBS Monday $5.50

2 · Reply

mickley32 Sep. 11 at 8:32 PM

$EBS solid volume!!

0 · Reply

KnuckleSandwich Sep. 11 at 7:30 PM

$EBS this is going to run next week!

0 · Reply

ComradeKomisar Sep. 11 at 6:10 PM

$EBS Looking like $MRNA is more important than the FED today.

0 · Reply

MC_Official Sep. 11 at 3:32 PM

🚨 OPENED: 📈 $EBS 7C 10/16 💰 Entry: $0.35

0 · Reply

KnuckleSandwich Sep. 11 at 3:30 PM

$EBS see you at double digits on the news!

0 · Reply

BavarianStallion Sep. 11 at 3:29 PM

$EBS nice

0 · Reply

alwayzwong Sep. 11 at 1:43 PM

$EBS would hate to be in fed Warsh’s in the position of “damned if you do/damned if you don’t raise rates”

0 · Reply

ComradeKomisar Sep. 10 at 8:02 PM

$EBS Yeah, here we go. Someone got out the last second. Too risky to keep capital here while CPI and FED are coming down the road. 2.4M shares total exchanged hands. 2x the daily average.

0 · Reply

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

2026-09-01T12:00:24.000Z - 12 days ago

Emergent BioSolutions announces $24M modification from BARDA

Sep 1, 2026, 7:55 AM EDT - 12 days ago

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

2026-08-31T12:00:20.000Z - 13 days ago

Emergent awarded standing offer by Government of Canada for Narcan Nasal Spray

Aug 31, 2026, 7:55 AM EDT - 13 days ago

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Aug 31, 2026, 7:54 AM EDT - 13 days ago

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

2026-08-21T10:35:29.000Z - 23 days ago

Emergent BioSolutions reinstated with an Underweight at JPMorgan

Aug 17, 2026, 1:38 PM EDT - 27 days ago

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law

Aug 11, 2026, 10:07 AM EDT - 4 weeks ago

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions

2026-08-10T10:10:21.000Z - 4 weeks ago

Emergent BioSolutions price target lowered to $10 from $12 at H.C. Wainwright

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

Emergent BioSolutions Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

Emergent BioSolutions Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

Emergent BioSolutions Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 weeks ago

Emergent BioSolutions Quarterly report: Q2 2026

Aug 5, 2026, 4:07 PM EDT - 5 weeks ago

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

Aug 5, 2026, 4:07 PM EDT - 5 weeks ago

Emergent BioSolutions Reports Second Quarter 2026 Financial Results

Jul 22, 2026, 4:01 PM EDT - 7 weeks ago

Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-06-29T13:25:30.000Z - 2 months ago

Emergent BioSolutions awarded $52.7M contract modification

Jun 29, 2026, 9:13 AM EDT - 2 months ago

Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government

Jun 23, 2026, 8:00 AM EDT - 2 months ago

BioMendics Receives FDA Fast Track Designation for BM-3103 (TolaSure® Gel™) for Epidermolysis Bullosa Simplex

Jun 8, 2026, 2:00 PM EDT - 3 months ago

Emergent BioSolutions Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:02 AM EDT - 3 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid Overdose

Jun 3, 2026, 1:20 PM EDT - 3 months ago

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T21:00:59.000Z - 3 months ago

Emergent BioSolutions awarded $64.5M HHS contract modification

May 28, 2026, 4:01 PM EDT - 3 months ago

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

May 20, 2026, 7:30 AM EDT - 3 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

2026-05-18T13:18:07.000Z - 3 months ago

Emergent BioSolutions receives Saudi approval for ACAM2000 vaccine

May 18, 2026, 8:59 AM EDT - 3 months ago

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

May 11, 2026, 7:53 AM EDT - 4 months ago

Hantavirus cases spark surge in pharma and biotech stocks — here's why

INO MRNA NVAX

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Slides: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 4 months ago

Emergent BioSolutions Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 4 months ago

Emergent BioSolutions Reports First Quarter 2026 Financial Results

2026-04-30T13:58:59.000Z - 4 months ago

Emergent BioSolutions receives Singapore regulatory approval for ACAM2000

Apr 30, 2026, 7:55 AM EDT - 4 months ago

Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Emergent BioSolutions Transcript: AGM 2026

2026-04-29T12:30:52.000Z - 4 months ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

SABS

Apr 29, 2026, 7:35 AM EDT - 4 months ago

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Apr 29, 2026, 6:53 AM EDT - 4 months ago

Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives

2026-04-28T12:59:14.000Z - 4 months ago

Emergent BioSolutions reports Imojev manufacturing pact with Substipharm

Apr 28, 2026, 8:01 AM EDT - 4 months ago

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 4:05 PM EDT - 5 months ago

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Apr 16, 2026, 4:05 PM EDT - 5 months ago

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing

2026-04-09T20:31:33.000Z - 5 months ago

Emergent BioSolutions teams with British Columbia on Take-Home Naloxone Program

Apr 9, 2026, 4:25 PM EDT - 5 months ago

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Apr 7, 2026, 8:05 AM EDT - 5 months ago

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

2026-03-25T20:26:40.000Z - 5 months ago

Emergent BioSolutions announces over $60M in government contract awards

Mar 25, 2026, 4:15 PM EDT - 5 months ago

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing

Mar 17, 2026, 12:49 PM EDT - 6 months ago

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

SIGA

2026-03-09T10:10:22.000Z - 6 months ago

Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright

Mar 3, 2026, 8:00 AM EST - 6 months ago

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Slides: Q4 2025

Feb 26, 2026, 4:05 PM EST - 6 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 4:01 PM EST - 6 months ago

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Feb 26, 2026, 4:01 PM EST - 6 months ago

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Feb 12, 2026, 6:00 PM EST - 7 months ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Feb 12, 2026, 9:02 AM EST - 7 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Jan 15, 2026, 1:08 PM EST - 8 months ago

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Jan 14, 2026, 8:15 PM EST - 8 months ago

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 8 months ago

Emergent BioSolutions Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 8 months ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 8, 2026, 4:30 PM EST - 8 months ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 8:00 AM EST - 8 months ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 7, 2026, 7:59 AM EST - 8 months ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 12, 2025, 8:30 AM EST - 9 months ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Nov 18, 2025, 8:00 AM EST - 9 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 12, 2025, 4:01 PM EST - 10 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Slides: Q3 2025

Oct 29, 2025, 4:15 PM EDT - 10 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 8, 2025, 7:45 AM EDT - 11 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Unicorn2020 Sep. 13 at 5:31 PM

1 · Reply

billywilliamz Sep. 11 at 8:56 PM

$EBS Monday $5.50

2 · Reply

mickley32 Sep. 11 at 8:32 PM

$EBS solid volume!!

0 · Reply

KnuckleSandwich Sep. 11 at 7:30 PM

$EBS this is going to run next week!

0 · Reply

ComradeKomisar Sep. 11 at 6:10 PM

$EBS Looking like $MRNA is more important than the FED today.

0 · Reply

MC_Official Sep. 11 at 3:32 PM

🚨 OPENED: 📈 $EBS 7C 10/16 💰 Entry: $0.35

0 · Reply

KnuckleSandwich Sep. 11 at 3:30 PM

$EBS see you at double digits on the news!

0 · Reply

BavarianStallion Sep. 11 at 3:29 PM

$EBS nice

0 · Reply

alwayzwong Sep. 11 at 1:43 PM

$EBS would hate to be in fed Warsh’s in the position of “damned if you do/damned if you don’t raise rates”

0 · Reply

ComradeKomisar Sep. 10 at 8:02 PM

$EBS Yeah, here we go. Someone got out the last second. Too risky to keep capital here while CPI and FED are coming down the road. 2.4M shares total exchanged hands. 2x the daily average.

0 · Reply

KnuckleSandwich Sep. 10 at 8:02 PM

$EBS volume and positive move indicates there is a leak about contract award... get ready EBS is going for a run!

0 · Reply

ComradeKomisar Sep. 10 at 6:24 PM

$EBS Pretty strange price action before a large macro data event (CPI), and FED tea leaf reading speculation. Usually gamblers sell, but today they are buying back what they sold yesterday. I would have expected another down day.

2 · Reply

alwayzwong Sep. 10 at 12:02 AM

$EBS -6.66$ YtD

0 · Reply

Nuesta Sep. 9 at 3:50 PM

$EBS https://www.marketbeat.com/instant-alerts/analyst-emergent-biosolutions-ebs-buy-rating-reaffirmed-at-hc-wainwright-2026-09-09/ HC Wainwright reaffirming Buy rating.

0 · Reply

Chromada06 Sep. 9 at 3:47 PM

$EBS just as I was starting to have a bit of fomo while I was waiting to lock in losses I’m reminded of the pain this stock is.. like a bad ex gf I just keep coming back to. 😭

1 · Reply

westparktrader Sep. 9 at 3:33 PM

$EBS my man put back those shares from 4.60 to 6.60 now he's ready to use that fire power to drop it back to 5.25

0 · Reply

ComradeKomisar Sep. 7 at 8:42 PM

$EBS Borrowing premiums for 'shit-cos' have been on the rise since Trump's "Liberation Day" last year. This board will really need to refi the notes by Aug next year. They need to get the balance down to $200M or less for that. I highly suspect they will announce a surprise $50M note buyback program for Q4, which will be seen as highly credible considering the fast execution of the $75M note buyback they just did.

1 · Reply

ComradeKomisar Sep. 4 at 10:48 PM

$EBS I think Chadwick here, of Ohio, could save our bacon. He's built a 2% stake(+160% from the prior quarter), and usually Ancora move to shake up boards. I was quite surprised that Emergent made good so fast on the $75M notes buyback, and i suspect it is because the board is noticing these guys breathing down their neck. The stock is clearly being punished not just because of Narcan, but because the Orbimed covenants, while better than OHA, remain a millstone on all our collective necks. Don't know what they would propose, but it surely it will be to ringfence the MCM business from Narcan. Watch for that 13F to turn into a 13D for a clearer signal, but that fast execution of the notes buyback is pretty clear IMHO. https://archive.ph/dXZBR

1 · Reply

ComradeKomisar Sep. 4 at 8:18 PM

$EBS Whew! Finally pivoting away from RFK Jr. and HHS, and into DoW and Kadlec. https://www.nytimes.com/2026/09/04/us/politics/pentagon-nih-biodefense-agreement.html

3 · Reply

Lopppendbuffet Sep. 4 at 7:29 PM

$SIGA Department of war made new agrements $SIGA $EBS

1 · Reply

ZacksResearch Sep. 4 at 12:14 PM

💰 $EBS is taking another step to strengthen its balance sheet Emergent BioSolutions has completed the repurchase of $75M of senior unsecured notes, reducing its outstanding unsecured debt while maintaining flexibility for its broader transformation strategy. Key takeaways: • Repurchased $75M of 3.875% senior unsecured notes due 2028 • Used approximately $68M in cash, buying the notes at an average 90.6% of face value • Outstanding balance now stands at approximately $364.7M • Emergent retains access to another $50M under its asset-based revolving facility • Management is evaluating the best timing to refinance the remaining notes ahead of their August 2028 maturity Price target breakdown here 👇 https://www.zacks.com/stock/research/EBS/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-39496&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_39496

0 · Reply

Market Cap	319.43M
Revenue (ttm)	742.90M
Net Income (ttm)	52.60M
EPS (ttm)	N/A
PE Ratio	4.08
Forward PE	45.15
Profit Margin	7.08%
Debt to Equity Ratio	1.70

Volume	1,299,100
Avg Vol	1,124,618
Day's Range	N/A - N/A
Shares Out	51.27M
Stochastic %K	66%
Beta	2.34
Analysts	Sell
Price Target	$10.00